Jasper Therapeutics completes IgAN enrollment for vensobafusp alfa Phase 2; adds FSGS cohort

Jasper Therapeutics, Inc.

18 IgAN patients enrolled in stage 1 across 3 cohorts: subcutaneous Q2W (n=6), Q4W (n=6) and Q8W (n=6) maintenance dosing.
Initial interim IgAN data from the Phase 2 basket study expected by year-end 2026; stage 1 assesses safety, tolerability and initial efficacy.
New FSGS cohort added to the basket study, with first patients anticipated to be dosed in the first quarter of 2027.
Study runs in China with partner Kira; vensobafusp alfa (KP104) is a bifunctional biologic targeting both alternative and terminal complement pathways.
CMO Greg Keenan said enrollment completed on schedule; company is exploring additional cohorts in other complement-mediated kidney diseases.

This headline and bullets were generated automatically by deepseek-v4.1-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.